Periodic Reporting for period 4 - CARBALIVE (Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease.)

The goal of the CARBALIVE consortium was to improve outcomes in patients with cirrhosis and non-alcoholic liver disease (NAFLD). During the course of the grant period, the Consortium members agreed to focus on the cirrhotic patients as a means of ensuring the delivery of a...